|  |
| --- |
| I. Project Title |
|  | **Date:** |
| **II. Project Group Investigators (Please list names and institutes of all investigators)** *(for external investigator- it is required to include at least 1 ILCCO/TRICL investigator in the Project Group)* |
|

|  |  |  |  |
| --- | --- | --- | --- |
| **Author/Co-author Name** | **Institution** | **Phone Number** | **Email** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

 |
| III. Background |
|  |
| IV. Specific Aims |
|  |
| **V. Methods** |
|  |
| **VI. Materials or variables needed from the study PIs (Please separate out the required vs optional components)** |
|  |
| **VII. Time line** |
|  |
| **VIII. Funding Sources and Declaration of Conflict of Interests.** *To ensure full transparency and to protect collaborating study PIs, ILCCO/TRICL requires the Project Leaders to disclose any circumstances that could give rise to a potential conflict of interests related to the proposed project activity in particular, or to lung cancer and/or tobacco products in general, including but not limited to funding sources, employment and consulting, board membership and investment interests within the last 5 years.*  |
|  |
| **IX. Other remarks** (e.g. **publication** plan, etc) |
|  |
| **X. Scope/Focus of your proposal (see definition below)** |
| Scope: 1=Genome-Wide, 2=Gen-Sets, 3=Targeted Regions, 4=Specific Pathway.Focus: 1=Risk, 2=Prognosis, 3=Both Risk and Prognosis, 4=Method, 5=Other Phenotype, 6=Interactions |